The control of velogenic Newcastle disease virus (VNDV) is still a serious challenge, especially in endemic localities in Egypt. The phylogenetic proximity between used vaccines and field viruses can definitely protect against repeated NDV outbreaks. Therefore, the aim of the this work is to prepare a secure, sterile and potent an oil inactivated vaccine from a recent local isolate genotype VII 1.1 "NDV-CH-EGY-GIZA-VVTNRC-2021" and evaluates its efficacy against commercially available NDV genotype II vaccines in broiler chickens. Eighty chickens were housed in four groups (A, B, C and D) of 20 birds per group. Group A has been received the experimentally prepared inactivated genotype VII NDV vaccine by day 9 old, subsequently primed and boostered with commercial live attenuated genotype VII vaccine at 7 and 21 days-of age. While group B was treated with commercial live and killed genotype II NDV vaccines at the same days, respectively. Furthermore, groups C and D act as positive and negative non-vaccinated controls. At 30 days of age groups A, B and C were challenged with VNDV genotype VII1.1 isolate, where the clinical manifestations, gross post-mortem lesions, Humoral immune response and also quantification of virus shed postchallenge (PC) via real-time QRT-PCR were all screened and precisely recorded. The results revealed that, group A chickens developed the highest humoral antibody titers throughout the vaccination schedule and conferred a complete protection against mortality with milder clinical signs, moreover displayed a significant decrease in the shedding of NDV with drastically blocked shedding 7 days PC compared to group B with little clinical protection, higher mortalities, lower antibody titers and longest viral shedding PC. In conclusion, the NDV genotype VII-based vaccines homologous to challenge virus ensure a significant control on VNDV in terms of clinical protection, mortality, and virus shedding than the genotype II classic vaccines heterologous to the endemic virus in broiler chickens.